

SS ISO 14155 : 2020
ISO 14155:2020, IDT
(ICS 11.100.20)

SINGAPORE STANDARD

**Clinical investigation of medical devices for
human subjects — Good clinical practice**

SS ISO 14155 : 2020

ISO 14155:2020, IDT
(ICS 11.100.20)

SINGAPORE STANDARD

**Clinical investigation of medical devices for human
subjects — Good clinical practice**

Published by Enterprise Singapore

All rights reserved. Unless otherwise specified, no part of this Singapore Standard may be reproduced or utilised in any form or by any means, electronic or mechanical, including photocopying and microfilming, without permission in writing from Enterprise Singapore. Request for permission can be sent to: standards@enterprisesg.gov.sg.

© ISO 2020

© Enterprise Singapore 2020

ISBN 978-981-49-2545-7

The content of this Singapore Standard was approved on 10 December 2020 by the Biomedical and Health Standards Committee (BHSC) under the purview of the Singapore Standards Council.

First published, 2017

First revision, 2021

BHSC consists of the following members:

	Name	Representation
Chairman	: Dr Yong Chern Chet	<i>Individual Capacity</i>
Deputy Chairmen	: Mr Vincent Cheung	<i>Individual Capacity</i>
	Adj Asst Prof Selina Seah	<i>Changi General Hospital</i>
	Ms Wong Woei Jiuang	<i>Health Sciences Authority</i>
Advisor	: Ms Jacqueline Monteiro	<i>Individual Capacity</i>
Secretary	: Mr Kevin Tan	<i>Singapore Manufacturing Federation – Standards Development Organisation</i>
Members	: Mr Abel Ang	<i>Advanced MedTech Holdings</i>
	Mr Terri Chin	<i>Singapore Manufacturing Federation (Testing, Inspection and Certification Interest Group)</i>
	Mr Alec Chow Boon Kuan	<i>Medtronic International Ltd</i>
	Assoc Prof Raymond Chua	<i>Ministry of Health</i>
	Ms Heidi Goh	<i>Singapore Manufacturing Federation (Medical Technology Industry Group)</i>
	Prof James Goh	<i>Biomedical Engineering Society (Singapore)</i>
	Dr Joel Lee	<i>Nanyang Polytechnic</i>
	Mr Lee Suen Ming	<i>Parkway East Hospital</i>
	Dr Daniel Li	<i>Integrated Health Information Systems Pte Ltd</i>
	Ms Audrey Lok	<i>Enterprise Singapore</i>
	Dr Margam Chandrasekaran	<i>Individual Capacity</i>
	Dr Ong Siew Hwa	<i>Acumen Research Laboratories Pte Ltd</i>
	Dr Jipson Quah	<i>Singapore Medical Association</i>
	Dr Subramanian Venkatraman	<i>National University of Singapore (Industry Liaison Office)</i>
	Dr Sidney Yee	<i>Diagnostics Development Hub – Accelerate Technologies Pte Ltd</i>
	Dr Adrian Yeo	<i>Association of Biomedical Laboratory Professionals (Singapore)</i>

BHSC set up the Technical Committee on Medical Devices to oversee the preparation of this standard. The Technical Committee consists of the following members:

	Name	Representation
Chairman	: Prof James Goh	<i>Individual Capacity</i>
Secretary	: Mr Kevin Tan	<i>Singapore Manufacturing Federation – Standards Development Organisation</i>
Members	: Mr Chen Xiang	<i>Biosensors International Group</i>
	Ms Chua Chui Khim	<i>Becton Dickinson Medical Products Pte Ltd</i>
	Dr Christopher Lam	<i>Health Sciences Authority</i>
	Assoc Prof Leo Hwa Liang	<i>National University Singapore</i>
	Dr Lim Jing	<i>Osteopore International Pte Ltd</i>
	Ms Iris Tan	<i>Individual Capacity</i>

The Technical Committee sets up the National Mirror Working Group for ISO/TC 194 to prepare this standard. The Working Group consists of the following experts who contribute in their *individual capacity*:

	Name
Convenor	: Dr Margam Chandrasekaran
Deputy Convenor	: Dr Ong Lee Lee
Secretary	: Mr She Long Huai
Members	: Assoc Prof Chew Sing Yan
	Mr Fan Mingwei
	Ms Heidi Goh
	Prof James Goh
	Mr Peter Haywood
	Prof James Hui Hoi Po
	Dr Lim Jing
	Assoc Prof Phan Toan-Thang
	Prof Seeram Ramakrishna
	Mr Tan Ming Jie
	Dr Tang Kin Fai

The organisations in which the experts of the Working Group are involved are:

Biomedical Engineering Society (Singapore)
Cordlife Group Limited
Denova Sciences Pte Ltd
Edwards Lifesciences (Singapore) Pte Ltd
Emcero Pte Ltd
Health Sciences Authority

*Nanyang Technological University
National University of Singapore
Osteopore International Pte Ltd
Wise Consultants and Services Pte Ltd*

Contents

	Page
National Foreword.....	7
Foreword	8
1 Scope	10
2 Normative references	10
3 Terms and definitions.....	10
4 Summary of good clinical practice (GCP) principles.....	20
5 Ethical considerations	21
5.1 General	21
5.2 Improper influence or inducement	21
5.3 Compensation and additional health care.....	21
5.4 Registration in publicly accessible database.....	21
5.5 Responsibilities	21
5.6 Communication with the ethics committee (EC)	22
5.7 Vulnerable populations	23
5.8 Informed consent	24
6 Clinical investigation planning	29
6.1 General	29
6.2 Risk management.....	29
6.3 Justification for the design of the clinical investigation	30
6.4 Clinical investigation plan (CIP)	31
6.5 Investigator's brochure (IB).....	31
6.6 Case report forms (CRFs).....	31
6.7 Monitoring plan.....	32
6.8 Investigation site selection.....	33
6.9 Agreement(s)	33
6.10 Labelling.....	33
6.11 Data monitoring committee (DMC).....	33
7 Clinical investigation conduct.....	34
7.1 General	34
7.2 Investigation site initiation	34
7.3 Investigation site monitoring.....	34
7.4 Adverse events and device deficiencies	34
7.5 Clinical investigation documents and documentation.....	36
7.6 Additional members of the investigation site team	37
7.7 Subject privacy and confidentiality of data.....	37

7.8	Document and data control.....	37
7.10	Accounting for subjects.....	40
7.11	Auditing.....	40
8	Suspension, termination, and close-out of the clinical investigation	41
8.1	Completion of the clinical investigation.....	41
8.2	Suspension or premature termination of the clinical investigation.....	41
8.3	Routine close-out.....	42
8.4	Clinical investigation report	43
8.5	Risk assessment and conclusions.....	43
8.6	Document retention	43
9	Responsibilities of the sponsor	44
9.1	Clinical quality management.....	44
9.2	Clinical investigation planning and conduct	44
9.3	Outsourcing of duties and functions	51
9.4	Communication with regulatory authorities.....	51
10	Responsibilities of the principal investigator	52
10.1	General	52
10.2	Qualification of the principal investigator.....	52
10.3	Qualification of investigation site.....	52
10.4	Communication with the EC	52
10.5	Informed consent process	53
10.6	Compliance with the CIP	53
10.7	Medical care of subjects.....	54
10.8	Safety reporting.....	55
	Annex A (normative) Clinical investigation plan (CIP)	56
	Annex B (normative) Investigator's brochure (IB).....	66
	Annex C (informative) Case report forms (CRFs).....	69
	Annex D (normative) Clinical investigation report.....	71
	Annex E (informative) Essential clinical investigation documents	77
	Annex F (informative) Adverse event categorization.....	85
	Annex G (informative) EC responsibilities	87
	Annex H (informative) Application of ISO 14971 to clinical investigations	91
	Figure H.1 — Application of ISO 14971 to the management of potential safety concerns in a clinical investigation	91
	Annex I (informative) Clinical development stages.....	92
	Annex J (informative) Clinical investigation audits.....	97
	Bibliography	100

National Foreword

This Singapore Standard was prepared by the National Mirror Working Group for ISO/TC 194 set up by the Technical Committee on Medical Devices under the purview of BHSC.

It is a revision of SS ISO 14155 : 2017 “Clinical investigation of medical devices for human subjects – Good clinical practice”.

This standard is an identical adoption of ISO 14155:2020, “Clinical investigation of medical devices for human subjects – Good clinical practice”, published by the International Organization for Standardization.

NOTE – Reference to International Standards are replaced by applicable Singapore Standards/Technical References.

Attention is drawn to the possibility that some of the elements of this Singapore Standard may be the subject of patent rights. Enterprise Singapore shall not be held responsible for identifying any or all of such patent rights.

NOTE

- 1. Singapore Standards (SSs) and Technical References (TRs) are reviewed periodically to keep abreast of technical changes, technological developments and industry practices. The changes are documented through the issue of either amendments or revisions. Where SSs are deemed to be stable, i.e. no foreseeable changes in them, they will be classified as “Mature Standards”. Mature Standards will not be subject to further review, unless there are requests to review such standards.*
- 2. An SS or TR is voluntary in nature except when it is made mandatory by a regulatory authority. It can also be cited in contracts making its application a business necessity. Users are advised to assess and determine whether the SS or TR is suitable for their intended use or purpose. If required, they should refer to the relevant professionals or experts for advice on the use of the document. Enterprise Singapore and the Singapore Standards Council shall not be liable for any damages whether directly or indirectly suffered by anyone or any organisation as a result of the use of any SS or TR. Although care has been taken to draft this standard, users are also advised to ensure that they apply the information after due diligence.*
- 3. Compliance with a SS or TR does not exempt users from any legal obligations.*

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, *Biological and clinical evaluation of medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This third edition cancels and replaces the second edition (ISO 14155:2011), which has been technically revised. The main changes to the previous edition are as follows:

- inclusion of a summary section of GCP principles (see Clause 4);
- reference to registration of the clinical investigation in a publicly accessible database (see 5.4);
- inclusion of clinical quality management (see 9.1);
- inclusion of risk-based monitoring (see 6.7);
- inclusion of statistical considerations in Annex A;
- inclusion of guidance for ethics committees in Annex G;
- reinforcement of risk management throughout the process of a clinical investigation (planning to consideration of results) including Annex H;

- clarification of applicability of the requirements of this document to the different clinical development stages (see Annex I);
- inclusion of guidance on clinical investigation audits (see Annex J).

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Clinical investigation of medical devices for human subjects — Good clinical practice

1 Scope

This document addresses good clinical practice for the design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the clinical performance or effectiveness and safety of medical devices.

For post-market clinical investigations, the principles set forth in this document are intended to be followed as far as relevant, considering the nature of the clinical investigation (see Annex I).

This document specifies general requirements intended to

- protect the rights, safety and well-being of human subjects,
- ensure the scientific conduct of the clinical investigation and the credibility of the clinical investigation results,
- define the responsibilities of the sponsor and principal investigator, and
- assist sponsors, investigators, ethics committees, regulatory authorities and other bodies involved in the conformity assessment of medical devices.

NOTE 1 Users of this document need to consider whether other standards and/or national requirements also apply to the investigational device(s) under consideration or the clinical investigation. If differences in requirements exist, the most stringent apply.

NOTE 2 For Software as a Medical Device (SaMD) demonstration of the analytical validity (the SaMD's output is accurate for a given input), and where appropriate, the scientific validity (the SaMD's output is associated to the intended clinical condition/physiological state), and clinical performance (the SaMD's output yields a clinically meaningful association to the target use) of the SaMD, the requirements of this document apply as far as relevant (see Reference [4]). Justifications for exemptions from this document can consider the uniqueness of indirect contact between subjects and the SaMD.

This document does not apply to *in vitro* diagnostic medical devices. However, there can be situations, dependent on the device and national or regional requirements, where users of this document might consider whether specific sections and/or requirements of this document could be applicable.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 14971, *Medical devices — Application of risk management to medical devices*